EUVIMEDEUVIMED entdecken
Crossref

2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin X

Madeline G Dans iD, Jon Kyle Awalt iD, Nghi Nguyen, Josephine Palandri, Anna Ngo, Kate E Jarman, Jin H Jeon, Tomas Yeo, Heekuk Park, Anne-Catrin Uhlemann iD, Emma Y Mao, Maria R Gancheva und 12 weitere

ACS Infectious Diseases · 14.08.2026 · 12 (8) · 2713-2726

DOI: 10.1021/acsinfecdis.6c00258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 09.07.2026. Verfasst von Madeline G Dans und 23 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research , Parkville3052, Australia. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Aspartic Acid Endopeptidases, Quinazolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Howard Hughes Medical Institute, Wellcome Trust, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of resistance to most clinically used antimalarials necessitates the discovery of new chemotypes. A phenotypic screen against asexual Plasmodium falciparum identified the 2-amino-3,4-dihydroquinazoline scaffold, previously developed as a β-secretase 1 inhibitor for Alzheimer’s disease. Evaluation of hit analogues against malarial aspartyl proteases revealed potent inhibition of plasmepsin X. Structure-activity analysis showed that key motifs on the hit scaffold are required for driving biochemical and antimalarial but are associated with poor selectivity against human aspartyl proteases and low metabolic stability. Plasmepsin X was validated as the molecular target through forward genetics, activity against mutant parasites, and inhibition of plasmepsin X substrate processing. 2-Amino-3,4-dihydroquinazoline analogs exhibit moderate asexual killing rates, low-to-moderate resistance risk, no cross-resistance with multidrug-resistant strains, and transmission-blocking activity. Further optimization of potency and metabolic stability will be required to achieve in vivo efficacy and realize the potential of this antimalarial class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumAspartic Acid EndopeptidasesQuinazolinesProtozoan ProteinsHumansStructure-Activity RelationshipAnimalsDrug ResistanceMalaria, Falciparum

Stichwörter der Autor:innen

Plasmodiumantimalarialmalariaplasmepsinβ-secretase

Substanzen

AntimalarialsAspartic Acid EndopeptidasesQuinazolinesplasmepsinProtozoan Proteins

Autor:innen und Institutionen

  • The Walter and Eliza Hall Institute of Medical Research , Parkville3052, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville3010, Australia.
  • Department of Microbiology & Immunology, Columbia University Irving Medical Center, New YorkNew York10032, United States.
  • Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New YorkNew York10032, United States.
  • Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New YorkNew York10032, United States.
  • Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Adelaide5005, Australia.

ORCID-Profile: Madeline G Dans, Jon Kyle Awalt, Anne-Catrin Uhlemann, Mojca Kristan, Delphine Baud, Brad E Sleebs

Förderung

  • Howard Hughes Medical Institute
  • Wellcome Trust
  • National Health and Medical Research Council
  • Medicines for Malaria Venture

Zitieren

APA

Dans, M. G., Awalt, J. K., Nguyen, N., Palandri, J., Ngo, A., Jarman, K. E., Jeon, J. H., Yeo, T., Park, H., Uhlemann, A. C., Mao, E. Y., Gancheva, M. R., Wilson, D. W., Mukherjee, P., Chakraborty, A., Kristan, M., Stewart, L., Sutherland, C. J., Baud, D., …, & Sleebs, B. E. (2026). 2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin X. ACS Infectious Diseases, 12(8), 2713-2726. https://doi.org/10.1021/acsinfecdis.6c00258

Vancouver

Dans MG, Awalt JK, Nguyen N, Palandri J, Ngo A, Jarman KE, et al. 2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin X. ACS Infectious Diseases. 2026;12(8):2713-2726. doi:10.1021/acsinfecdis.6c00258

BibTeX
@article{Dans2026,
  author = {Dans, Madeline G and Awalt, Jon Kyle and Nguyen, Nghi and Palandri, Josephine and Ngo, Anna and Jarman, Kate E and Jeon, Jin H and Yeo, Tomas and Park, Heekuk and Uhlemann, Anne-Catrin and Mao, Emma Y and Gancheva, Maria R and Wilson, Danny W and Mukherjee, Partha and Chakraborty, Arnish and Kristan, Mojca and Stewart, Lindsay and Sutherland, Colin J and Baud, Delphine and Brand, Stephen and Fidock, David A and Jackson, Paul F and Cowman, Alan F and Sleebs, Brad E},
  title = {2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin X},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {8},
  pages = {2713--2726},
  doi = {10.1021/acsinfecdis.6c00258}
}
Kostenlos starten →